2013
DOI: 10.1089/omi.2012.0083
|View full text |Cite
|
Sign up to set email alerts
|

Redundancy Control in Pathway Databases (ReCiPa): An Application for Improving Gene-Set Enrichment Analysis in Omics Studies and “Big Data” Biology

Abstract: Unparalleled technological advances have fueled an explosive growth in the scope and scale of biological data and have propelled life sciences into the realm of ''Big Data'' that cannot be managed or analyzed by conventional approaches. Big Data in the life sciences are driven primarily via a diverse collection of

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
31
0

Year Published

2014
2014
2021
2021

Publication Types

Select...
4
4
2

Relationship

0
10

Authors

Journals

citations
Cited by 39 publications
(33 citation statements)
references
References 34 publications
0
31
0
Order By: Relevance
“…O mics is a systems science raising both promises and challenges from cell to society to bioeconomy (Akondi and Lakshmi, 2013;Bernabò et al, 2013;Birch and Tyfield, 2013;Bowler et al, 2013;Dove, 2013;Rajan, 2013;Vivar et al, 2013). A key challenge and opportunity is the rapid growth of published literature that makes biomedical text mining increasingly invaluable so as to unpack implicit knowledge hidden in unstructured text.…”
Section: Introductionmentioning
confidence: 99%
“…O mics is a systems science raising both promises and challenges from cell to society to bioeconomy (Akondi and Lakshmi, 2013;Bernabò et al, 2013;Birch and Tyfield, 2013;Bowler et al, 2013;Dove, 2013;Rajan, 2013;Vivar et al, 2013). A key challenge and opportunity is the rapid growth of published literature that makes biomedical text mining increasingly invaluable so as to unpack implicit knowledge hidden in unstructured text.…”
Section: Introductionmentioning
confidence: 99%
“…In support of that, despite the evidence about the relationship of CYP2D6 and drug response [6], the combined use of parallel alternate metabolic CYP pathways [23] that can compensate in the case of CYP2D6 PMs to individualize treatments with certain CYP2D6 sub- strates is, as yet, very limited, as is use of other genes such as those encoding drug receptors also involved in response [24]. Finally, individualized therapy to increase drug safety in different populations will also largely benefit from collecting and interrogating large genomics datasets in order to identify biological mechanisms associated with observed outcomes [25].…”
Section: Discussionmentioning
confidence: 99%
“…Our developed mapping strategy between different graph representations of analogous pathways enabled us to objectively compare pathway enrichment results that otherwise would have been conducted manually and subjectively. Furthermore, they allowed us to generate super pathways inspired by previous approaches that have shown the benefit of merging similar pathway representations (Stoney et al, 2018;Vivar et al, 2013;Doderer et al, 2012;Belinky et al, 2015). In this case, this was made possible by the fully harmonized gene sets and networks generated by our previous work, ComPath and PathMe.…”
Section: /21mentioning
confidence: 99%